Suppr超能文献

失笑活血汤对子宫腺肌病患者疼痛、肿瘤坏死因子-α及白细胞介素-8的影响

Effects of Shixiao Huoxue Decoction on pain, tumor necrosis factor-α, and interleukin-8 in patients with adenomyosis.

作者信息

Li Weihua, Shao Chao, Liang Jing

机构信息

Department of Gynecology, South District of Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine Beijing 102611, China.

出版信息

Am J Transl Res. 2024 Feb 15;16(2):584-591. doi: 10.62347/VQVR4400. eCollection 2024.

Abstract

OBJECTIVE

To explore the effect of Shixiao Huoxue Decoction on pain and tumor necrosis factor (TNF)-α and interleukin (IL)-8 levels in patients with adenomyosis.

METHODS

A total of 65 patients with adenomyosis admitted to South District of Guang'anmen Hospital from January 2020 to December 2021 were divided into two groups according to the treatment methods. The control group was treated with pregnatrienone, and the study group was treated with additional Shixiaohuoxue decoction. The incidence of complications, treatment efficacy, levels of inflammatory factors, Traditional Chinese Medicine symptom score, dysmenorrhea score, menstrual volume score, dysmenorrhea symptom score, changes in uterine volume, level of insulin-like growth factor 1 (IGF-1), and changes in the level of carbohydrate antigen (CA125) were observed before and after treatment in both two groups. Univariate Logistic analysis showed that uterine volume, IGF-1, CA125, serum IL-8 and TNF-α were correlated with the short-term efficacy of Meixiaohuoxue Decoction in the treatment of uterine adenomyosis (P<0.05).

RESULTS

The levels of IL-8 and TNF-α in the study group were significantly lower than those in the control group after treatment (P<0.05). The scores of dyspareunia and non-menstrual pelvic pain in the study group were significantly lower than those in the control group (P<0.05). The overall response rate in the study group (93.75%) was significantly higher than that in the control group (66.66%) (P<0.05). The scores of Traditional Chinese Medicine symptoms, dysmenorrhea, menstrual volume, and dysmenorrhea symptoms in the study group were significantly lower than those in the control group after treatment (P<0.05). The IGF-1 and CA125 levels in the study group were significantly lower than those in the control group after treatment (P<0.05). However, no significant difference in uterine volume was found between the two groups after treatment (P>0.05).

CONCLUSION

Xiaoxiao Huoxue Decoction demonstrated a better treatment efficacy in patients with adenomyosis through improving dysmenorrhea and Traditional Chinese Medicine symptoms, as well as reducing the levels of body inflammatory factors, non-menstrual pelvic pain, and dyspareunia, thus contributing to early recovery of patients. Therefore, Xiaoxiao Huoxue Decoction is worthy of promotion in clinical treatment of adenomyosis.

摘要

目的

探讨失笑活血汤对子宫腺肌病患者疼痛及肿瘤坏死因子(TNF)-α和白细胞介素(IL)-8水平的影响。

方法

选取2020年1月至2021年12月在广安门医院南区收治的65例子宫腺肌病患者,根据治疗方法分为两组。对照组采用孕三烯酮治疗,研究组在孕三烯酮基础上加用失笑活血汤治疗。观察两组治疗前后并发症发生率、治疗效果、炎症因子水平、中医症状评分、痛经评分、月经量评分、痛经症状评分、子宫体积变化、胰岛素样生长因子1(IGF-1)水平及糖类抗原(CA125)水平变化。单因素Logistic分析显示,子宫体积、IGF-1、CA125、血清IL-8和TNF-α与失笑活血汤治疗子宫腺肌病的近期疗效相关(P<0.05)。

结果

治疗后研究组IL-8和TNF-α水平显著低于对照组(P<0.05)。研究组痛经及非经期盆腔疼痛评分显著低于对照组(P<0.05)。研究组总有效率(93.75%)显著高于对照组(66.66%)(P<0.05)。治疗后研究组中医症状、痛经、月经量及痛经症状评分显著低于对照组(P<0.05)。治疗后研究组IGF-1和CA125水平显著低于对照组(P<0.05)。然而,两组治疗后子宫体积差异无统计学意义(P>0.05)。

结论

失笑活血汤通过改善痛经和中医症状,降低机体炎症因子水平、非经期盆腔疼痛及痛经程度,对子宫腺肌病患者有较好的治疗效果,有助于患者早日康复。因此,失笑活血汤在子宫腺肌病临床治疗中值得推广。

相似文献

1
Effects of Shixiao Huoxue Decoction on pain, tumor necrosis factor-α, and interleukin-8 in patients with adenomyosis.
Am J Transl Res. 2024 Feb 15;16(2):584-591. doi: 10.62347/VQVR4400. eCollection 2024.
2
[Treatment of adenomyosis patients by bushen huoxue sanyu decoction: a clinical study].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1302-5.
4
[Evaluation of the efficacy of GnRH-a pretreatment before total hysterectomy for adenomyosis patients: a propensity score matching analysis].
Zhonghua Fu Chan Ke Za Zhi. 2023 Aug 25;58(8):589-594. doi: 10.3760/cma.j.cn112141-20230607-00257.
6
Laparoscopic Uterine Artery Occlusion Combined with Uterine-sparing Pelvic Plexus Block and Partial Adenomyomectomy for Adenomyosis: A Video Case Report.
J Minim Invasive Gynecol. 2021 Oct;28(10):1681-1684. doi: 10.1016/j.jmig.2021.05.015. Epub 2021 May 26.

引用本文的文献

1
Research Advances in Adenomyosis-Related Signaling Pathways and Promising Targets.
Biomolecules. 2024 Nov 4;14(11):1402. doi: 10.3390/biom14111402.

本文引用的文献

2
Berberine attenuates hyperalgesia in mice with adenomyosis.
Arch Gynecol Obstet. 2022 Jul;306(1):115-125. doi: 10.1007/s00404-022-06438-y. Epub 2022 Mar 1.
3
Adenomyosis: Diagnosis and Management.
Am Fam Physician. 2022 Jan 1;105(1):33-38.
4
Transcriptome analysis of eutopic endometrium in adenomyosis after GnRH agonist treatment.
Reprod Biol Endocrinol. 2022 Jan 12;20(1):13. doi: 10.1186/s12958-021-00881-3.
5
The Effect of Uterine Adenomyosis on IVF Outcomes: a Systematic Review and Meta-analysis.
Reprod Sci. 2022 Nov;29(11):3177-3193. doi: 10.1007/s43032-021-00818-6. Epub 2022 Jan 3.
7
Qiu's Neiyi Recipe Regulates the Inflammatory Action of Adenomyosis in Mice via the MAPK Signaling Pathway.
Evid Based Complement Alternat Med. 2021 Dec 11;2021:9791498. doi: 10.1155/2021/9791498. eCollection 2021.
8
Ultrasound-guided percutaneous microwave ablation of adenomyosis: a narrative review.
Ann Palliat Med. 2021 Nov;10(11):12003-12011. doi: 10.21037/apm-21-3133.
9
Effect of modified levonorgestrel-releasing intrauterine system in human adenomyosis with heavy menstrual bleeding.
J Obstet Gynaecol Res. 2022 Jan;48(1):161-168. doi: 10.1111/jog.15031. Epub 2021 Oct 21.
10
Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.
Reprod Biol Endocrinol. 2021 Jul 21;19(1):114. doi: 10.1186/s12958-021-00800-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验